Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Cipla was at the forefront of the pharmaceutical industry’s response to the Covid-19 pandemic, whether by tying up with MNCs for products like remdesivir or tocilizumab, or ramping up production of drugs that are more common but still necessary. Having won the Company of the Year Award for 2020-21, Cipla’s executive vice-chairperson SAMINA HAMIED and managing director and global chief executive officer UMANG VOHRA spoke with Sohini Das about their experience of the pandemic and their plans for inorganic growth. Edited excerpts:

Tell us about how you were mentored by YK Hamied and MK Hamied when you joined Cipla.

Vohra: